MLH1 and endometrial cancer: The majority of the referrals were from patients with MLH1 absent endometrial cancer (n = 188); follow‐up MLH1 promoter hypermethylation was performed on cases where patients consented to further testing (n = 95), and for those patients with negative hypermethylation (n = 13), 23% were found to carry a germline mutation.